[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100285296":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":37,"collaborators":40,"id":51,"slug":7,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":7,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":7,"maxAge":7,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"State University of New York at Buffalo","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Thomas J. Langan, MD","Clinical Director, Clinical Research, Institute for Myelin and Glial Exploration","PRINCIPAL_INVESTIGATOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","716-888-4732","tjlangan@buffalo.edu",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Amy Barczykowski","716-829-6101","alp38@buffalo.edu",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"RECRUITING","Buffalo","New York","14203","United States",{"type":30,"coordinates":31},"Point",[32,33],-78.87837,42.88645,{"lat":33,"lon":32},[36],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":12,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Thomas J. Langan","Principal Investigator",[41,44,47,49],{"name":42,"class":43},"Rare Diseases Clinical Research Network","NETWORK",{"name":45,"class":46},"National Center for Advancing Translational Sciences (NCATS)","NIH",{"name":48,"class":6},"Lysosomal Disease Network",{"name":50,"class":46},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","100285296",false,"NCT02993796","Krabbe Disease Global Patient Registry","The Institute for Myelin and Glia Exploration's Clinical Database of Patients With Krabbe Disease, A World-Wide Registry","Inclusion Criteria:\n\n* Anyone diagnosed with Krabbe disease\n* Anyone at-risk for Krabbe disease\n* Family members of someone diagnosed with, or at-risk for, Krabbe disease.\n\nExclusion Criteria:\n\n* Anyone who is not diagnosed with, or at-risk for, Krabbe disease\n* Anyone who is not a family member of someone diagnosed with, or at-risk for, Krabbe disease","ALL",{"count":59,"type":60},60,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of this study is to develop a clinical database of individuals diagnosed with Krabbe disease in order to determine which symptoms herald the onset of clinical disease in the various phenotypes of Krabbe disease; to determine whether level of GALC enzyme activity, or a specific genetic mutation predict the clinical course; and to determine which neurodiagnostic tests predict onset and\u002For severity of the disease.",[65],"Krabbe Disease",[67,68,69,70],"Krabbe disease","globoid cell leukodystrophy","galactosylceramide lipidosis","sphingolipidosis","2025-02-07",{"date":73,"type":74},"2025-02-10","ACTUAL",{"date":76,"type":74},"2014-09",{"date":78,"type":60},"2026-09",{"name":5,"class":6},1]